Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 3
1985 2
1986 3
1988 3
1989 6
1993 4
1994 6
1995 4
1996 4
1997 3
1998 8
1999 2
2000 3
2001 1
2002 1
2003 1
2004 1
2006 2
2008 2
2009 4
2010 5
2011 3
2012 3
2013 2
2014 3
2015 4
2016 1
2017 8
2018 4
2019 2
2020 4
2021 3
2022 5
2023 2
2024 7
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG, Griffin M, Langemeijer S, Usuki K, Kulagin A, Ogawa M, Yu J, Mujeebuddin A, Nishimura JI, Lee JW, Peffault de Latour R; 301/302 Study Group. Kulasekararaj AG, et al. Eur J Haematol. 2022 Sep;109(3):205-214. doi: 10.1111/ejh.13783. Epub 2022 Jun 16. Eur J Haematol. 2022. PMID: 35502600 Free PMC article. Clinical Trial.
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Mauro FR, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Frigeri F, Albano F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F, Liberati AM, Merli F, Morello L, Musuraca G, Tani M, Ibatici A, Regazzoni G, Di Candia M, Palma M, Arienti D, Molica S. Mauro FR, et al. Among authors: galieni p. Cancers (Basel). 2024 Mar 20;16(6):1228. doi: 10.3390/cancers16061228. Cancers (Basel). 2024. PMID: 38539561 Free PMC article.
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial.
Russo D, Polverelli N, Bernardi S, Santarone S, Farina M, Borlenghi E, Onida F, Castagna L, Bramanti S, Carella AM, Sorasio R, Martino M, Alati C, Olivieri A, Beltrami G, Curti A, Vetro C, Leotta S, Mancini V, Terruzzi E, Bernardi M, Galieni P, Musto P, Cerretti R, Giaccone L, Skert C, Radici V, Vezzoli M, Calza S, Leoni A, Garuffo L, Bonvicini C, Pellizzeri S, Malagola M, Ciceri F. Russo D, et al. Among authors: galieni p. Lancet Haematol. 2024 Nov;11(11):e830-e838. doi: 10.1016/S2352-3026(24)00241-2. Epub 2024 Sep 20. Lancet Haematol. 2024. PMID: 39312920 Clinical Trial.
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
D'Agostino M, Rota-Scalabrini D, Belotti A, Bertamini L, Arigoni M, De Sabbata G, Pietrantuono G, Pascarella A, Tosi P, Pisani F, Pescosta N, Ruggeri M, Rogers J, Olivero M, Garzia M, Galieni P, Annibali O, Monaco F, Liberati AM, Palmieri S, Stefanoni P, Zamagni E, Bruno B, Calogero RA, Boccadoro M, Musto P, Gay F. D'Agostino M, et al. Among authors: galieni p. Blood Cancer J. 2024 Jun 7;14(1):94. doi: 10.1038/s41408-024-01075-x. Blood Cancer J. 2024. PMID: 38849344 Free PMC article. Clinical Trial.
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Farina M, Scaini MC, Facchinetti A, Leoni A, Bernardi S, Catoni C, Morello E, Radici V, Frioni F, Campodonico E, Traverso G, Cavallaro G, Olivieri A, Galieni P, Renzo ND, Patriarca F, Carluccio P, Skert C, Maffini E, Pellizzeri S, Campisi G, Re F, Benedetti E, Rosato A, Almici C, Chiusolo P, Peccatori J, Malagola M, Poggiana C, Russo D. Farina M, et al. Among authors: galieni p. Transplant Cell Ther. 2024 Jun;30(6):580.e1-580.e14. doi: 10.1016/j.jtct.2024.03.026. Epub 2024 Apr 4. Transplant Cell Ther. 2024. PMID: 38582286 Free article.
Advanced Stage Hodgkin Lymphoma: Patient Management.
Gini G, Cimminiello M, Galieni P, Hohaus S, Nassi L, Picardi M, Romano A, Tarantini G. Gini G, et al. Among authors: galieni p. Acta Biomed. 2020 May 25;91(S-5):5-12. doi: 10.23750/abm.v91iS-5.9913. Acta Biomed. 2020. PMID: 32525129 Free PMC article.
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation.
Nozzoli C, Pucillo M, Giaccone L, Rambaldi A, Stanghellini MTL, Benedetti E, Russo D, Mordini N, Mangiacavalli S, Bernasconi P, Parma M, Carluccio P, Galieni P, Rivela P, Martino M, Chiusolo P, Isola M, De Martino M, Oldani E, Degrandi E, Boncompagni R, Antonioli E, Carnevale F, Tozzi M, Selleri C, Fanin R, Patriarca F; Gruppo Italiano Trapianto Midollo Osseo (GITMO). Nozzoli C, et al. Among authors: galieni p. Transplant Cell Ther. 2024 Nov 4:S2666-6367(24)00744-9. doi: 10.1016/j.jtct.2024.10.015. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39505212
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: galieni p. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, Morè S, Corradini P, Ledda A, Gentile M, De Sabbata G, Pietrantuono G, Pascarella A, Tosi P, Curci P, Gilestro M, Capra A, Galieni P, Pisani F, Annibali O, Monaco F, Liberati AM, Palmieri S, Luppi M, Zambello R, Fazio F, Belotti A, Tacchetti P, Musto P, Boccadoro M, Gay F. Bertamini L, et al. Among authors: galieni p. J Clin Oncol. 2022 Sep 20;40(27):3120-3131. doi: 10.1200/JCO.21.01393. Epub 2022 Jun 6. J Clin Oncol. 2022. PMID: 35666982
109 results